Sangiovanni Timothy J. 4

What Happened
Timothy J. Sangiovanni, SVP Finance & Corporate Controller of Zevra Therapeutics (ZVRA), received equity awards on 2026-05-28: a grant of stock options covering 40,000 shares and an award of 20,000 restricted stock units (RSUs). Both awards have a $0 per-share acquisition price reported on the Form 4; these are compensation grants (not open-market purchases or sales).

Key Details

• Transaction date: May 28, 2026; Form 4 filed May 29, 2026 (appears timely).
• Options: 40,000-share option grant (derivative), exercise price reported as $0 on filing; vesting in four equal annual installments beginning March 1, 2027 (subject to continued service).
• RSUs: 20,000 restricted stock units (each converts to one share on settlement); vest one-third on March 1, 2027 and the remaining two-thirds in equal annual installments thereafter (subject to continued service).
• Shares owned after transaction: not specified in the information provided.
• Notable: Grants are governed by the issuer’s 2014 Equity Incentive Plan and are service-vested (no 10b5-1 plan, cashless exercise, or tax-withholding details disclosed in the provided footnotes).

Context
These awards are compensation-related derivative grants: options give the right to buy shares in the future (subject to vesting and plan terms) and RSUs are a contingent right to receive shares when they vest. Such grants are routine for employee compensation and do not by themselves indicate immediate buying or selling activity in the market.